Corbus announces first patient dosed in Phase 1 CRB-913 study

Corbus Pharmaceuticals (CRBP) announced the dosing of the first subject in the single ascending dose / multiple ascending dose portion of the Phase 1 trial of CRB-913 for the treatment of obesity. The study is being conducted in the United States under an open IND. CRB-913 is a second-generation, highly peripherally restricted cannabinoid type-1 receptor inverse agonist drug designed to treat obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss but the first generation of this class was abandoned due to the potential risk of neuropsychiatric adverse events. A second generation of peripherally restricted CB1 inverse agonists is now being explored. Pre-clinical data presented at Obesity Week 2024 demonstrated CRB-913 is markedly more peripherally restricted than both monlunabant and rimonabant. In non-clinical models, CRB-913 has a brain-to-plasma ratio fifty times lower than rimonabant and is fifteen times more peripherally restricted than monlunabant. The SAD/MAD portion of the Phase 1 trial is scheduled to be completed in Q3 of this year and the Company expects to commence a Phase 1b dose-range finding study in Q4 of 2025. The dose-range finding study is scheduled for completion in the second half of 2026.